Arciuolo D
No ORCID on file
· 9 papers in corpus
· active 2021-2025
Study types
- case-report 1
- letter 1
- other 1
Condition tags
- endometriosis 2
- die_deep_infiltrating 1
- disambig:endometritis 1
- adenomyosis 1
Top journals
Frequent coauthors
case-report
2025
The AFF2 gene encodes a protein involved in transcriptional regulation and chromatin remodeling. While primarily associated with Fragile X syndrome, AFF2 fusions have recently been identified in certain malignancies, mostly sinonasal squamo…
2025
BackgroundIntestinal-type vulvar adenocarcinoma (VAIt) is an exceptionally rare form of primary vulvar cancer, characterized by histological features resembling mucinous colonic carcinomas, including villo-glandular structures composed of g…
other
2025
Low-grade endometrial stromal sarcomas (LG-ESS) are the second most common malignant uterine mesenchymal tumors, but in contrast to the more common leiomyosarcomas, they are often characterized by a prolonged and relatively indolent course.…
2025
Sex cord-like endometrioid carcinoma (SCLEC) is an uncommon entity which may constitute a diagnostic challenge. This study aimed to perform a clinicopathological, immunohistochemical, and molecular reappraisal of ovarian SCLEC. Consecutive …
letter
2023
2023
The Role of Plasma Cells as a Marker of Chronic Endometritis: A Systematic Review and Meta-Analysis.
Chronic endometritis (CE) is the persistent inflammation of the endometrial lining associated with infertility and various forms of reproductive failures. The diagnosis of CE is based on the histological evidence of stromal plasma cells; ho…
2022
Pilomatrix-like high-grade endometrioid carcinoma (PiMHEC) has recently been described as an aggressive variant of endometrial carcinoma. Herein, we described a case of ovarian PiMHEC, comparing it to endometrial PiMHEC and assessing previo…
2021
BackgroundTo date, useful diagnostic applications of p16 IHC have been documented in gynecological pathology both for HPV-related and non-HPV-related lesions. In the present article, we reported our experience with the novel anti-p16 INK4a …
2021